The Problem With Cancer?
To Live With It.
We all have to live with the problem of cancer.
However cancer is a uniquely personal and unfathomably complex individual disease- in each and every case.
In this vital, life-transforming, life-or-death medical matter, isn’t it also the core problem for the Patient that the therapies available and delivered are not necessarily personalised and scheduled for the best possible outcome? For lifelong remission.
We ask:
- What Personal Data does the Patient (and Oncologist) receive, in direct evidence to the effectiveness of specific options, treatments given, and when?
Normax Biomed’s novel Educated Antigen Receptor Therapy (EARTh)™ GMP Process promises to deploy state-of-the-art technologies for truly personalized treatment, for the Patient and Oncologist, for this vital personal (n=1) need for immunotherapy as a safe and effective complement, in the tools of the trade, for the Oncologist, to treat People Living with Cancer with EARTh™ .
Men get cancer more often than women.1 Women have a lower survival rate than men.2 Personalized cancer therapy is needed.3
1. Bizuayehu HM, Dadi AF, Ahmed KY, et al.
Burden of 30 cancers among men: global statistics in 2022 and projections for 2050 using population-based estimates. Cancer. 2024; 1-16. doi:10.1002/cncr.35458
2. Global Burden of Disease Cancer Collaboration, Kocarnik JM, Compton K, et al.
Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019. JAMA Oncol. 2022; 8(3): 420-444.
3. Vera R, Juan-Vidal O, Safont-Aguilera MJ, de la Peña FA, Del Alba AG.
Sex differences in the diagnosis, treatment and prognosis of cancer: the rationale for an individualised approach. Clin Transl Oncol. 2023 Jul;25(7):2069-2076. doi: 10.1007/s12094-023-03112-w. Epub 2023 Feb 18. PMID: 36802013; PMCID: PMC10250517.
